Other: nbt-nm108 (0 g/day)    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica1

13. Multiple sclerosis/Neuromyelitis optica    [ 3,050 clinical trials,   2,147 drugs,   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways]
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 3,050 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04574024
(ClinicalTrials.gov)
January 11, 202121/9/2020HFP (High-Fiber Supplement) in MS (Multiple Sclerosis)Effect of High-fiber Supplement in Multiple SclerosisMultiple SclerosisDrug: NBT-NM108 (60 g/day);Other: NBT-NM108 (0 g/day)Suhayl Dhib-Jalbut, MDNULLNot yet recruiting21 Years55 YearsAll50Phase 1;Phase 2United States